insulin glargine + insulin glargine + insulin glargine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hyperglycemia
Conditions
Hyperglycemia, Diabetes
Trial Timeline
Jul 1, 2004 → May 1, 2005
NCT ID
NCT00338104About insulin glargine + insulin glargine + insulin glargine
insulin glargine + insulin glargine + insulin glargine is a approved stage product being developed by Sanofi for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00338104. Target conditions include Hyperglycemia, Diabetes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00338104 | Approved | Completed |
Competing Products
9 competing products in Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 | Merck | Phase 1 | 33 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| Olanzapine + Ziprasidone | Pfizer | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| Lantus® (insulin glargine) | Sanofi | Phase 1 | 32 |
| insulin glargine recombinant + therapeutic insulin | Sanofi | Phase 3 | 76 |